IMMUNOGLOBULIN, ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 SINGLE-CHAIN VARIABLE FRAGMENT VH-LINKER-VL) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN C-REGION C-TERMINAL FRAGMENT), (257->230'),(260->233')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 ANTI-(HUMAN LYMPHOCYTE ACTIVATION GENE-3) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 .KAPPA.-CHAIN
Advanced or Metastatic Solid Tumors
Xencor, Inc.monoclonal_antibodyPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 73/ 100
Competitive context
62 Active assets in the Advanced or Metastatic Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Hanmi Pharmaceutical Company Limited | Phase 1/2 | B |
Epirubicin Hanmi Pharmaceutical Company Limited | Phase 1/2 | B |
Cyclophosphamide Beijing Biotech | Phase 1/2 | B |
Eloxatin ASLAN Pharmaceuticals | Phase 1/2 | CCC |
CIS-DIAMMINEDICHLOROPLATINUM II Merck Sharp & Dohme LLC | Phase 1/2 | CCC |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN, ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 SINGLE-CHAIN VARIABLE FRAGMENT VH-LINKER-VL) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN C-REGION C-TERMINAL FRAGMENT), (257->230'),(260->233')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 ANTI-(HUMAN LYMPHOCYTE ACTIVATION GENE-3) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 .KAPPA.-CHAIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →